Imfinzi (durvalumab) Letter of Medical Necessity
Imfinzi (durvalumab) is a PD-L1 inhibitor with its most prominent indication in unresectable Stage III NSCLC following concurrent chemoradiation (PACIFIC trial). It also holds approvals in ES-SCLC, biliary tract cancer, and HCC. PA requires careful documentation of disease stage, chemoradiation regimen details, and treatment timing.
FDA-Approved Indications
- ● unresectable Stage III NSCLC (after concurrent chemoradiation)
- ● extensive-stage small cell lung cancer (first-line with etoposide + carboplatin/cisplatin)
- ● biliary tract cancer (first-line with gemcitabine + cisplatin)
- ● hepatocellular carcinoma (first-line with tremelimumab — STRIDE regimen)
- ● limited-stage SCLC (consolidation after chemoradiation)
Why Imfinzi Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Stage III NSCLC disease progression prior to consolidation not excluded (tumor must not have progressed during/after CRT)
- 2. Concurrent vs sequential chemoradiation not specified (must be concurrent for PACIFIC indication)
- 3. PD-L1 status not provided (although not required, payers may request it)
- 4. ECOG performance status not documented
- 5. Combination regimen components not fully specified for BTC/HCC indications
- 6. Prior platinum-based CRT not documented for NSCLC
What to Include in a Imfinzi Letter of Medical Necessity
For Stage III NSCLC, document pathology-confirmed NSCLC, clinical stage III (unresectable), concurrent (not sequential) platinum-based chemoradiation completion, no disease progression during/after CRT (confirmation required), ECOG PS 0-1, and initiation within 1–42 days of CRT completion per PACIFIC protocol. For BTC and HCC, document pathology-confirmed histology, liver function (Child-Pugh A), prior systemic therapy history, and ECOG status.
Key clinical evidence to cite:
- ✓ PACIFIC trial — significantly improved OS (mOS 47.5 vs 29.1 months) in Stage III NSCLC post-CRT
- ✓ CASPIAN trial — improved OS with durvalumab + etoposide/platinum in ES-SCLC
- ✓ TOPAZ-1 — improved OS in biliary tract cancer (first IO approval in BTC)
- ✓ HIMALAYA — improved OS with STRIDE regimen in HCC
Relevant guidelines:
- 📖 NCCN NSCLC Guidelines (Category 1)
- 📖 NCCN SCLC Guidelines
- 📖 NCCN Hepatobiliary Cancers Guidelines
- 📖 ASCO Stage III NSCLC Guideline
Imfinzi Prior Authorization Criteria
Standard criteria across major US payers for Imfinzi. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Stage III NSCLC disease progression prior to consolidation not excluded (tumor must not have progressed during/after CRT)
- → Prior platinum-based CRT not documented for NSCLC
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Imfinzi
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Imfinzi Prior Authorization FAQ
Why was my Imfinzi prior authorization denied?
The most common denial reasons for Imfinzi are: Stage III NSCLC disease progression prior to consolidation not excluded (tumor must not have progressed during/after CRT); Concurrent vs sequential chemoradiation not specified (must be concurrent for PACIFIC indication); PD-L1 status not provided (although not required, payers may request it); ECOG performance status not documented; Combination regimen components not fully specified for BTC/HCC indications; Prior platinum-based CRT not documented for NSCLC.
What should a Imfinzi Letter of Medical Necessity include?
For Stage III NSCLC, document pathology-confirmed NSCLC, clinical stage III (unresectable), concurrent (not sequential) platinum-based chemoradiation completion, no disease progression during/after CRT (confirmation required), ECOG PS 0-1, and initiation within 1–42 days of CRT completion per PACIFIC protocol. For BTC and HCC, document pathology-confirmed histology, liver function (Child-Pugh A), prior systemic therapy history, and ECOG status.
Which payers cover Imfinzi?
Imfinzi is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.